We believe that AI has the potential to revolutionize how cancer and other complex diseases are diagnosed and treated. We also believe that AI is a tool, not an identity – without access to high quality data and a scientifically rigorous, transparent approach to model development, AI is just a buzzword. That's where we come in.
Aignostics is a spin-off from one of Europe's largest and most prestigious university hospitals (Charité), with employees in Berlin and New York. We have received over $50M in funding from leading investors and are a growing team of over 100 interdisciplinary professionals. We work with academic partners as well as leading global life sciences companies.
APCT1_DE